稳心颗粒冲剂治疗心血管神经症124例临床研究

Clinical study of Wenxinkeli in the treatment of 124 cases of cardiovascular neurosis

目的:观察稳心颗粒冲剂治疗心血管神经症的临床疗效及安全性。方法:将心血管神经症患者124例随机分为两组,观察组在常规治疗的基础上合用稳心颗粒冲剂,对照组在常规治疗的基础上合用氟哌噻吨美利曲辛片(黛力新),4周为一个疗程,随访3个月,观察疗效及药物不良反应。结果:观察组疗效优于对照组,两组疗效比较差异有统计学意义(Z=2.515,P<0.05)。观察组的药物不良反应低于对照组。结论:稳心颗粒冲剂治疗心血管神经症安全有效,且药物不良反应少,值得临床推广。

Objective：To observe the clinical efficacy and the safety of Wenxinkeli in the treatment of cardiovascular neurosis. Methods： 124 patients with cardiovascular neurosis were randomly divided into two groups, the observation group were given routine treatment combined with Wenxinkeli, the control group were given routine treatment combined with Flupentixol and Melitracen Tablets,4 weeks for a course of treatment, followed up for 3 months, observed the efficacy and adverse drug reactions. Results：The clinical efficacy of the observation group was better than the control group, there was statistical difference（ Z = 2. 515, P 〈 0.05 ）. The adverse drug reactions of the observation group wwere lower than the control group. Conclusion： Wenxinkeli treatment of cardiovaseular neurosis is safe and effective, and less adverse drug reactions ,have the value of clinical promotion.